Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys

• DOI: 10.1007/s00406-016-0692-7
• Publication Date: 2016-04-18T15:54:46Z
• Authors: Kenji Hashimoto; Takeharu Kakiuchi; Hiroyuki Ohba; Shingo Nishiyama; Hideo Tsukada
• Keywords: Psychotomimetic; Raclopride; Ventral striatum; Binding potential

R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative esketamine (S-ketamine), since it might free of psychotomimetic side effects. Using [11C]raclopride positron emission tomography (PET), we investigated whether can affect dopamine D2/3 receptor binding in the conscious monkey brain. A single infusion (0.5 mg/kg), but not caused reduction availability striatum. This study suggests that unlike R-ketamine, cause release striatum, its associated with effects esketamine.